Summary

Gufic BioSciences Limited (Gufic) is a generic pharmaceutical company. It carries out development, manufacturing and marketing of pharmaceutical, generics, herbal, API’s and healthcare products. The company’s product portfolio includes ridol, optifer, lotril, rabol plus, shapers, stretch nil, livpar, sallaki, eugynin, zulcer and others. Its products find application in various therapeutic segments including anti-infectives, orthopaedic disorders, gynaecological disorders, and gastrointestinal disorders. The company’s products are used in treatment of diseases such as diarrhea, iron deficiency anemia, bacterial infections, indigestion, acute and chronic pain, dyspepsia and diabetis, among others. Gufic offers products in various formulations including tablets, capsules, ointments, syrups and suspensions, injections, powders, and lotions. Gufic is headquartered in Mumbai, Maharashtra, India.

Gufic BioSciences Limited Key Recent Developments

May 19, 2014: Gufic Biosciences Ltd Announces Resignation of Its Secretary and Compliance Officer
Nov 09, 2012: Gufic BioSciences Reports Revenue Of INR237m In Q2 Fiscal 2013
Aug 14, 2012: Gufic BioSciences Reports Revenue Of INR271.4m In Q1 Fiscal 2013
Jun 12, 2012: Gufic BioSciences Reports Revenue Of INR835.7m In Fiscal 2012
Feb 14, 2012: Gufic BioSciences Reports Revenue Of INR219.6m In Q3 Fiscal 2012

This comprehensive SWOT profile of Gufic BioSciences Limited provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including*,



- Business description – A detailed description of the company’s operations and business divisions.

- Corporate strategy – Analyst’s summarization of the company’s business strategy.

- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.

- Company history – Progression of key events associated with the company.

- Major products and services – A list of major products, services and brands of the company.

- Key competitors – A list of key competitors to the company.

- Key employees – A list of the key executives of the company.

- Executive biographies – A brief summary of the executives’ employment history.

- Key operational heads – A list of personnel heading key departments/functions.

- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities – A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.



Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,



You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.



Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.



Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.



Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.



Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Table Of Contents

Table of Contents

Section 1 - About the Company

Gufic BioSciences Limited - Key Information
Gufic BioSciences Limited - Overview
Gufic BioSciences Limited - Key Employees
Gufic BioSciences Limited - Key Employee Biographies
Gufic BioSciences Limited - Key Operational Heads
Gufic BioSciences Limited - Major Products and Services
Gufic BioSciences Limited - History
Gufic BioSciences Limited - Company Statement
Gufic BioSciences Limited - Locations And Subsidiaries
Gufic BioSciences Limited - Key Manufacturing facilities
Head Office
Other Locations and Subsidiaries

Section 2 - Company Analysis

Gufic BioSciences Limited - Business Description
Gufic BioSciences Limited - Corporate Strategy
Gufic BioSciences Limited - SWOT Analysis
SWOT Analysis - Overview
Gufic BioSciences Limited - Strengths
Gufic BioSciences Limited - Weaknesses
Gufic BioSciences Limited - Opportunities
Gufic BioSciences Limited - Threats
Gufic BioSciences Limited - Key Competitors

Section 3 - Company Financial Performance Charts

Gufic BioSciences Limited - Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 - Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer


Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Gufic BioSciences Limited, Key Information
Gufic BioSciences Limited, Key Ratios
Gufic BioSciences Limited, Share Data
Gufic BioSciences Limited, Major Products and Services
Gufic BioSciences Limited, History
Gufic BioSciences Limited, Key Employees
Gufic BioSciences Limited, Key Employee Biographies
Gufic BioSciences Limited, Key Operational Heads
Gufic BioSciences Limited, Other Locations
Gufic BioSciences Limited, Subsidiaries
Gufic BioSciences Limited, Key Manufacturing facilities
Gufic BioSciences Limited, Key Competitors
Gufic BioSciences Limited, SWOT Analysis
Gufic BioSciences Limited, Ratios based on current share price
Gufic BioSciences Limited, Annual Ratios
Gufic BioSciences Limited, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Tables

Gufic BioSciences Limited, Performance Chart
Gufic BioSciences Limited, Ratio Charts

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Drug Discovery and Development in United States: Omeros Corporation – Product Pipeline Review – H2 2011

Drug Discovery and Development in United States: Omeros Corporation – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • September 2014
  • by Global Markets Direct

The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from ...

Pharmaceutical in Japan: Astellas Pharma Inc. – Product Pipeline Review – H2 2011

Pharmaceutical in Japan: Astellas Pharma Inc. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • September 2014
  • by Global Markets Direct

- Product Pipeline Review - H2 2011” provides a detailed overview on the Astellas Pharma Inc.’s research and development focus. The report includes data on current developmental pipeline, complete ...

Pathology in United States: Boehringer Ingelheim GmbH – Product Pipeline Review – H2 2011

Pathology in United States: Boehringer Ingelheim GmbH – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • September 2014
  • by Global Markets Direct

The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from ...


7 Companies

Company Profiles


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.